|
|
|
|
Arzerra, Fludara, and Cytoxan Promising for Previously Untreated CLL
The combination of Arzerra (ofatumumab), Fludara (fludarabine), and Cytoxan (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL).These results were presented at the 2009 annual meeting of the...
|
|
|
BioVex names new vice president
(Datamonitor via COMTEX) -- BioVex, a biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, has appointed Tim Hanke as the new vice president of commercial operations.Mr Hanke will be...
|
|
|
BioVex Appoints Tim Hanke as VP Commercial Operations
- BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that it has appointed Tim Hanke as VP Commercial Operations.Hanke will be responsible for...
|
|
|
BioVex Appoints Tim Hanke as VP Commercial Operations
WOBURN, Mass.-- (BUSINESS WIRE) -- BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that it has appointed Tim Hanke as VP Commercial Operations.
|
|
|
BioVex Appoints Tim Hanke as VP Commercial Operations
BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that it has appointed Tim Hanke as VP Commercial Operations.Hanke will be responsible for...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ - News) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara...
|
|
|
Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
Oral Presentation of Interim Data Given at the American Society of Hematology Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 7, 2009 - Genzyme Corporation (Nasdaq: GENZ) announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath ...
|
